Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Leslie Dan Faculty of Pharmacy, University of Toronto, Institute for Clinical Evaluative Sciences, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Value Health. 2021 Sep;24(9):1279-1284. doi: 10.1016/j.jval.2021.04.1274. Epub 2021 Jun 24.
Health systems (nonfederal hospitals and clinics) are the second major source for drug expenditure in the United States. Opioids prescribed in these healthcare settings are commonly short-acting opioids that can lead to persistent opioid use. Nevertheless, there are no national data that describe trends in opioid use and the associated expenditure in health systems. Therefore, the objective of this article was to describe opioid use and expenditures in US health systems from 2015 to 2019.
We used data from IQVIA National Sales Perspectives to describe prescription opioid expenditure and use in health systems (nonfederal hospitals and clinics).
Over the 5-year study period, health systems dispensed a total of 6.55 billion units of opioids (26.88% decrease) with an associated expenditure of $3.33 billion (26.78% decrease). Relative to all opioid formulations in our study, oxycodone, hydrocodone, and fentanyl were the opioids with the highest use in US health systems. All opioid prescriptions decreased except fentanyl use, which increased by 29.80% in clinics. The use of abuse-deterrent formulations of opioids decreased by 51.00% over the study period, although the decrease seems to be driven mainly by long-acting oxycodone (brand name Oxycontin).
Opioid use and expenditures in health systems have been decreasing following national trends from retail pharmacies. Nevertheless, fentanyl use increased in clinics and was prescribed at higher proportions in nonfederal hospitals than other opioids, which warrants further investigation.
医疗体系(非联邦医院和诊所)是美国药物支出的第二大来源。这些医疗环境中开出的阿片类药物通常是短效阿片类药物,可能导致持续使用阿片类药物。然而,目前没有全国性的数据描述医疗体系中阿片类药物使用和相关支出的趋势。因此,本文的目的是描述 2015 年至 2019 年美国医疗体系中阿片类药物的使用和支出情况。
我们使用 IQVIA 全国销售透视数据来描述医疗体系(非联邦医院和诊所)中处方阿片类药物的支出和使用情况。
在 5 年的研究期间,医疗体系共开出了 65.5 亿剂阿片类药物(减少 26.88%),相关支出为 33.3 亿美元(减少 26.78%)。在我们的研究中,相对于所有阿片类药物制剂,羟考酮、氢可酮和芬太尼是美国医疗体系中使用最多的阿片类药物。除了芬太尼的使用增加了 29.80%外,所有阿片类药物的处方都有所减少,而芬太尼的使用在诊所中增加了。滥用阿片类药物的制剂在研究期间减少了 51.00%,尽管这种减少似乎主要是由长效羟考酮(商品名奥施康定)驱动的。
随着零售药店全国范围内的趋势,医疗体系中的阿片类药物使用和支出一直在减少。然而,芬太尼在诊所中的使用有所增加,在非联邦医院中的处方比例高于其他阿片类药物,这需要进一步调查。